Lexicon Genetics Licenses Valentis GeneSwitch Technology | GenomeWeb

NEW YORK, August 1 – Lexicon Genetics has licensed Valentis' GeneSwitch gene regulation technology for use in its functional genomics research, the companies said on Wednesday.

Lexicon, based in The Woodlands, Texas, is the third company to license the technology from Valentis after GlaxoSmithKline and Wyeth-Ayerst Laboratories signed similar deals earlier this year. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.